Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease

<p><strong>BACKGROUND:</strong> Chronic kidney disease (CKD) is associated with fluid excess which can be estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co-transporter 2 inhibition on bioimpedance-derived “Fluid Overload” and adiposity in a CKD...

Full description

Bibliographic Details
Main Authors:	Mayne, K, Haynes, R, Keane, D, Staplin, N, Judge, P, Preiss, D, Emberson, J, Dayanandan, R, Lee, R, Nolan, J, Omata, A, Landray, M, Baigent, C, Herrington, W
Other Authors:	EMPA-KIDNEY Bioimpedance Substudy Group
Format:	Journal article
Language:	English
Published:	American Society of Nephrology 2023

Similar Items

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
by: Preiss, D, et al.
Published: (2022)

Empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2022)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review
by: Mayne, KJ, et al.
Published: (2022)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
by: Staplin, N, et al.
Published: (2022)

Neprilysin inhibition in chronic kidney disease.
by: Judge, P, et al.
Published: (2014)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
by: Nangaku, M, et al.
Published: (2024)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Biliary tract and liver complications in polycystic kidney disease
by: Judge, P, et al.
Published: (2017)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
by: Haynes, R, et al.
Published: (2014)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Chronic kidney disease, heart failure and neprilysin inhibition
by: Haynes, R, et al.
Published: (2019)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
by: Lamprea-Montealegre, J, et al.
Published: (2019)

Effects of empagliflozin on right ventricular adaptation to pressure overload
by: Julie S. Axelsen, et al.
Published: (2023-12-01)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Benefits of lowering cholesterol in chronic kidney disease Reply
by: Baigent, C, et al.
Published: (2011)

Allocated but not treated: the silent 16% – Authors' reply
by: Horby, P, et al.
Published: (2022)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Abani, O, et al.
Published: (2023)

Effects of lowering LDL cholesterol on progression of kidney disease.
by: Haynes, R, et al.
Published: (2014)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Effect of processing delay and storage conditions on urine albumin-to-creatinine ratio
by: Herrington, W, et al.
Published: (2016)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
by: Herrington, W, et al.
Published: (2015)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
by: Staplin, N, et al.
Published: (2023)